$3.35 Billion is the total value of Carlyle Group Inc.'s 31 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCVX | New | Vaxcyte Inc | $72,079,962 | – | 1,923,158 | +100.0% | 2.15% | – |
| VRNA | New | Verona Pharma Plcsponsored ads | $49,346,600 | – | 2,457,500 | +100.0% | 1.47% | – |
| New | Hillevax Inc | $30,096,016 | – | 1,838,486 | +100.0% | 0.90% | – | |
| VERA | New | Vera Therapeutics Inccl a | $22,882,586 | – | 2,960,231 | +100.0% | 0.68% | – |
| PHAT | New | Phathom Pharmaceuticals Inc | $20,868,604 | – | 2,935,106 | +100.0% | 0.62% | – |
| New | Jasper Therapeutics Inc | $15,771,404 | – | 8,761,891 | +100.0% | 0.47% | – | |
| INVH | New | Invitation Homes Inc | $14,912,325 | – | 477,500 | +100.0% | 0.44% | – |
| RPHM | New | Reneo Pharmaceuticals Inc | $12,236,346 | – | 2,073,957 | +100.0% | 0.36% | – |
| ACET | New | Adicet Bio Inc | $12,163,464 | – | 2,115,385 | +100.0% | 0.36% | – |
| SPRB | New | Spruce Biosciences Inc | $6,401,305 | – | 2,896,518 | +100.0% | 0.19% | – |
| NCNA | New | Nucana Plcsponsored adr | $3,200,333 | – | 3,333,333 | +100.0% | 0.10% | – |
| PRTK | New | Paratek Pharmaceuticals Inc | $2,623,650 | – | 1,041,131 | +100.0% | 0.08% | – |
| New | Soleno Therapeutics Inc | $2,535,178 | – | 1,201,506 | +100.0% | 0.08% | – | |
| New | Effector Therapeutics Inc | $1,687,740 | – | 4,822,114 | +100.0% | 0.05% | – | |
| CBAY | New | Cymabay Therapeutics Inc | $1,143,944 | – | 131,036 | +100.0% | 0.03% | – |
| New | Sientra Inc | $256,058 | – | 167,358 | +100.0% | 0.01% | – | |
| New | Exicure Inc | $242,207 | – | 281,636 | +100.0% | 0.01% | – | |
| MTEM | New | Molecular Templates Inc | $75,020 | – | 200,000 | +100.0% | 0.00% | – |
| AGLE | New | Aeglea Biotherapeutics Inc | $69,024 | – | 240,500 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-05
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Wesco Aircraft Hldgs Inc | 28 | Q4 2019 | 16.8% |
| Seacor Marine Hldgs Inc | 22 | Q3 2023 | 1.1% |
| Enviva Partners LP | 21 | Q2 2020 | 31.5% |
| Enduro Rty Tr | 21 | Q1 2018 | 2.8% |
| USA Compression Partners LP | 20 | Q2 2018 | 28.5% |
| Pattern Energy Group Inc | 20 | Q3 2018 | 16.2% |
| Concord Med Svcs Hldgs Ltd | 19 | Q3 2017 | 1.1% |
| Superior Energy Svcs Inc | 19 | Q3 2017 | 0.7% |
| Cobalt Intl Energy Inc | 17 | Q1 2017 | 11.0% |
| Sequential Brnds Group Inc N | 17 | Q1 2020 | 1.7% |
View Carlyle Group Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Complete Solaria, Inc. | September 22, 2023 | 2,745,879 | 5.7% |
| Carlyle Credit Income Fund | September 14, 2023 | 4,785,628 | 41.0% |
| eFFECTOR Therapeutics, Inc. | August 18, 2023 | 4,829,891 | 7.8% |
| Vera Therapeutics, Inc. | August 02, 2023 | 1,872,764 | 4.2% |
| Reneo Pharmaceuticals, Inc. | May 09, 2023 | 2,730,457 | 8.2% |
| EXICURE, INC. | April 13, 2023 | 287,137 | 3.4% |
| SPRUCE BIOSCIENCES, INC. | February 23, 2023 | 3,734,518 | 9.2% |
| Vaxcyte, Inc. | February 10, 2023 | 2,070,724 | 2.6% |
| NuCana plc | August 11, 2022 | 3,353,134 | 6.4% |
| QuidelOrtho Corp | June 06, 2022 | 12,460,183 | 18.6% |
View Carlyle Group Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 10-Q | 2024-05-07 |
| 13F-HR | 2024-05-03 |
| 4 | 2024-05-03 |
| 4 | 2024-05-03 |
| 4 | 2024-05-03 |
| 4 | 2024-05-03 |
| 4 | 2024-05-03 |
| 4 | 2024-05-03 |
| 4 | 2024-05-03 |
| 4 | 2024-05-03 |
View Carlyle Group Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.